Lamiss Mohamed abd elaziz sad
Tanta University Hospital, Egypt
I was graduated very good with honor November 1997 from faculty of medicine Tanta University, Egypt then Msc in clinical oncology, Tanta University, Egypt 2004 after that MD in clinical oncology, Tanta University, Egypt 2010 I worked firstly as Resident in clinical oncology Department, Tanta university hospital, Egypt from July 1999 to July 2002. Then as demonstrator in clinical oncology department- faculty of medicine- Tanta University till July 2004. After that I worked as assistant lecturer of clinical oncology, University, Egypt 2004 till 2010. Now I am working as Lecturer of clinical oncology, Tanta University, Egypt from 2010 till present.
Back ground and aim:
Prognosis of hepatocellular carcinoma (HCC) is very poor and determining the prognosis rely many factors and we aim at defining the prognostic factor of macrophage migration inhibitory factor (MIF) , P53 and its correlation with other prognostic factors in HCC. Patients: Serum macrophage migration inhibitory factor and anti-p53 antibodies were measured in 139 patients diagnosed with HCC using a specific enzyme-linked immunosorbent assay (ELISA) kit. The clinicopathological characteristics of the patients were compared with respect to the presence of serum anti-p53 antibodies.
In univariate analysis, the prognostic factors with statistical significance were portal vein thrombosis, total serum bilirubin, serum albumin, serum AST, serum ALT, Prothrombin time , viral marker and anti p53 antibody and on multivariate analysis the prognostic factors were anti p53 antibody. Conclusion: Anti p53 antibody are associated with poor prognosis in HCC and it increased the prognostic potential of alpha fetoprotein. So p53can be used as target on HCC.